Detailed Narrative
Overall Financial Performance and FY26 Outlook
Glenmark Pharmaceuticals reported a consolidated revenue of INR32,562 million for Q4 FY25, marking a 6.3% year-over-year growth. For the full fiscal year 2025, consolidated revenue reached INR1,33,217 million, growing 12.8% YoY. The company provided an optimistic outlook for FY26, guiding for 10-12% revenue growth, an EBITDA margin of 19-20%, and cash generation between INR300-400 crores, primarily driven by core business performance.
Regional Performance Highlights
Europe demonstrated strong performance, growing nearly 20% in Q4 FY25 to INR7,335 million and contributing 21.4% to FY25 consolidated revenues, driven by its branded business. The ROW region also saw a 4.9% growth in Q4 to INR7,898 million, with strong contributions from Russia (10.2% secondary sales growth) and LatAm. North America, however, experienced a 5.4% decline in Q4 revenue to INR7,146 million due to a lack of significant new launches, though an uptick is anticipated from FY26 with upcoming respiratory and injectable product launches.
India Business Challenges and Strategic Shifts
India's formulation business recorded a modest 0.4% YoY growth in Q4 FY25, reaching INR9,430 million. This was primarily attributed to a weak acute respiratory market, intense competition in the diabetes segment leading to a 10% decline for Glenmark, and the strategic discontinuation of certain low-margin brands. To counter this, Glenmark is transitioning its diabetes portfolio from older molecules to newer ones like Lirafit, sitagliptin, and empagliflozin, with semaglutide launch planned, aiming to stabilize and grow the franchise.
Specialty and Innovation Pipeline Progress
Glenmark's specialty product RYALTRIS continues to perform well, now commercialized in over 45 markets globally, with an expected global sales target of $100 million for FY26. WINLEVI received approval from the U.K. MHRA in Q4 FY25, with a launch planned for FY26. The innovation entity, IGI, made significant progress with its lead asset ISB 2001, receiving Fast Track designation from the U.S. FDA in May 2025 and completing Phase I dose escalation, with further data to be presented at ASCO.
Manufacturing and Regulatory Updates
The Aurangabad plant underwent an inspection in September 2024 with zero observations, indicating strong compliance. However, the Pithampur plant's regulatory status remains under discussion with the FDA, though management noted minimal commercial impact. IGI announced the cessation of manufacturing at its La Chaux-de-Fonds facility in Switzerland, transferring activities to CDMOs to support higher volumes for future clinical programs, which also contributed to an exceptional loss in Q4.
Capital Allocation and Debt Management
Total asset additions for FY25 amounted to INR698 crores, with Q4 additions at INR309 crores. Net debt as of March 2025 stood at approximately INR489 crores. The company's working capital days were reported at 104, aligning with global peers. Interest expense in Q4 was INR66 crores, with a slight increase due to higher debt, but is expected to be lower in the coming year. The FY26 tax rate is projected to be 21-22%.